A gene therapy approach was taken to inhibit tumor growth by transfecting tumor cells with a plasmid encoding a truncated but active form of Pseudomonas exotoxin A (PE), using cationic lipids as the transfection reagent. Cells transfected with this plasmid express PE intracellularly and undergo apoptosis. Transfection was optimized in vitro using two cationic lipids, DOGS and DOSPER. A ratio of between 1:4 and 1:10 (wt/wt) was found to be optimal for DOSPER, and the ratio 1:4 was used for the in vivo study when a smaller injection volume was desired. Estimating the activity of the PE-encoding plasmid was done both directly, by counting cells in vitro after transfection, and by using a cytotoxicity assay, and indirectly, by cotransfecting the plasmid with a plasmid carrying a reporter ␤-galactosidase gene and observing a reduction in ␤-galactosidase activity with increasing amounts of the PE-encoding plasmid. The cotransfection method was found to be very sensitive, and showed transfection of cells even with 1-2 ng of the PE-encoding plasmid per 10 5 cells. Complexes of the PE-encoding plasmid together with cationic lipid were injected into tumor xenografts in athymic nude mice. The tumor growth of transfected tumors was attenuated compared with control untreated tumors or tumors transfected with a nontoxin-expressing vector. These results indicate the potential of such a treatment for attenuating solid tumor growth in vivo. Cancer Gene Therapy (2000) 7, 91-96
I
n recent years, efforts have been made to use gene therapy as a new approach for cancer therapy. 1 Targeting to tumors is achieved by different delivery systems, including viral and nonviral vectors. Also, different methods have been developed to increase the selectivity by selective targeting or selective gene expression. 2 Three major approaches are currently being explored for gene therapy for tumors: (a) boosting the immune system to reject the tumor, 3 (b) inducing tumor suppressor gene expression, 4 and (c) eradicating the tumor by delivery of a toxic gene. 5 In this study, the third approach was investigated using a plasmid encoding a truncated form of Pseudomonas exotoxin (PE) via cationic liposomes as the delivery vector.
The mechanism of cell killing by PE is through adenosine diphosphate ribosylation and by inactivation of elongation factor 2 and thus inhibition of protein synthesis. 6 -8 The truncated form of PE encoded by the plasmid used in this study (pULI100) has full activity in terms of protein synthesis inhibition (carried out by domain III of the toxin) and a portion of the toxin that is responsible for translocating to the cytosol (domain II); however, the binding domain (domain I), which is responsible for binding to ␣ 2 -macroglobulin receptor present on animal cells is, deleted. A cell transfected with this plasmid will express this truncated form of PE and will rapidly undergo apoptosis. 9 Cationic liposomes are one of the more attractive vectors for gene delivery in vivo, because they are not limited by the size of the DNA they carry, and although they are not as efficient as viral vectors, they are less toxic, not immunogenic, and can be produced in larger quantities than viral vectors. 10 -13 A large and growing number of cationic liposomes have been developed in the last several years. In this study, we chose to use cationic lipids with a multivalent cationic head group (spermine), dioctadecylamidoglycyl spermine (DOGS), and 1,3-di-oleoyloxy-2-(6-carboxy-spermyl)-propyl-amid (DOSPER). The cationic liposomes form a complex with DNA through charge interactions, and the net positively charged complex can interact with cells to produce successful transfections. Cationic liposomes can be administered intravenously. 14 -17 By intravenous injections, the lungs are the organ with the highest yields of transfection. Because of the probable lethality of transfection with PE and the probable damage to nontarget tissues, DNA-lipid complexes were injected directly into the tumor. To achieve sufficient cell killing for tumor regression, it is necessary to transfect a large number of cells with high efficiency. In this study, we show a sensitive means of estimating the efficiency of transfection, and the potential of transfection by intratumoral injections in vivo.
MATERIALS AND METHODS

Transfection
The transfection of cells in vitro was performed with the transfection reagents DOGS (Promega, Madison, Wis) and DOSPER (Boehringer Mannheim, Indianapolis, Ind). DOGS reagent was dissolved in ethanol. Ethanol was evaporated, and the dry lipid film was resuspended in a trace amount of ethanol and RPMI 1640. DNA diluted in RPMI 1640 was added. The mixture was incubated for 20 minutes at room temperature. DOSPER was diluted in 20 mM N-2-hydroxyethylpiperazine-NЈ-2-ethanesulfonic acid buffer and 150 mM NaCl (pH 7.4) and was mixed with DNA diluted in the same buffer to different DNA to lipid ratios.
DNA-lipid complexes were added to cells in media with and without sera and incubated for different time periods. After complexes had been removed, 2ϫ full supplemented media was added to the cells.
Assays for expression
An assay for ␤-galactosidase (␤-gal) expression was performed at 24 hours posttransfection by ␤-gal staining and by using an enzyme-linked immunosorbent assay (ELISA) kit for ␤-gal quantitation (Boehringer Mannheim). For ␤-gal staining, cells were washed and fixed in 2% formaldehyde and 0.2% glutaraldehyde in phosphate-buffered saline. Cells were then covered with a solution of 5-bromo-4-chloro-3-indolyl ␤-D-galactoside in 5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 2 mM MgCl 2 in PBS, and 2% agarose. Cells were incubated overnight at 37°C and checked under a microscope for blue transfected cells. The ELISA kit for ␤-gal quantitation was used to incubate cell lysates in plates covered with anti-␤-gal antibody.
Cell number was measured as follows: cells were washed extensively with PBS and trypsinized, and a fraction was counted in a Coulter counter (Coulter, Hialeah, Fla). Cell lysates were also assayed for protein concentration using Coomassie reagent (Pierce, Rockford, Ill). Cytotoxicity assays were performed using 96-well plates. Cells were plated at a density of 1.5 ϫ 10 4 cells/well 1 day before the assay. Cells were incubated for 20 hours with different amounts of DNA-lipid complexes and then pulsed with [ 3 H]leucine for 2 hours. After incubation, plates were frozen in dry ice, thawed, and processed in a harvester. Filter mats containing labeled protein were read in a Trilux ␤-counter (Wallace, Gaithersburg, Md). IC 50 was calculated to be the concentration of DNA to give 50% inhibition of protein synthesis. Plasmid construction pULI100 (plasmid encoding PE35KDEL) and pELI92 (plasmid encoding Escherichia coli lacZ) were derived from pCMV␤, which contains the cytomegalovirus promoter for expression in eukaryotic cells.
Tumor injections
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RESULTS
Optimization of lipid to DNA ratio
The charge ratio between the DNA and the cationic lipids is important in forming the right complex to yield the best transfection of cells. DNA-lipid complexes with different charge ratios can result in the formation of different particles, which have a large effect on the transfection yield. 19 Different charge ratios were tried ranging from 1:2 wt/wt of DNA to lipid, respectively (1:1.2 charge ratio), up to a ratio of 1:50 wt/wt (1:30 charge ratio). Transfection was measured together with cell viability in vitro. Transfection was performed on A431 cells using two cationic lipid reagents, DOGS and DOSPER, and the reporter gene ␤-gal. Transfection was also optimized for the incubation time and was determined to be 2 hours. ␤-gal expression was assayed by an ELISA kit and was also checked by ␤-gal staining (data not shown). Figure 1 shows that for the cationic lipid DOGS, a wt/wt ratio of 1:10 (DNA to DOGS) was optimal under the experimental conditions. The DOSPER reagent gave a better overall transfection efficiency, and a ratio of between 1:4 and 1:10 wt/wt gave maximal transfection yields. For the in vivo study, we desired to keep the volume of injection into the tumor as Figure 1 . Optimization of the DNA to cationic lipid wt/wt ratio was done in cell culture using the A431 cell line as a model, for both cationic lipid reagents. Transfection was done in duplicate using pELI92 as a reporter plasmid encoding ␤-gal. ␤-gal expression was determined using a ␤-gal ELISA kit.
small as possible; therefore a ratio of 1:4 (DNA to DOSPER) was used for the tumor experiments described below.
Assays for transfection yield and activity of PE-encoding plasmid Cells transfected with the plasmid encoding for PE are expected to produce the toxin and undergo apoptosis. For that reason, a direct way to measure the transfection yield and expression level of the PE-encoding plasmid (pULI100) is to count cells treated with DNA-lipid complexes in vitro. Figure 2 shows cells that were transfected with increasing amounts of pULI100. Control cells were transfected with another plasmid encoding ␤-gal (pELI92). In the figure, we can see that the number of cells per well for the cells transfected with the PE-encoding plasmid decreased with increasing amounts of DNA. The cells transfected with the PEencoding plasmid underwent apoptosis, which results in a decrease in cell number. The decrease in cell number could also be attributed to lipid toxicity, as we also observed a decrease in cell number for the control group, which was transfected with ␤-gal-encoding plasmid. However, the decrease in cell number in the cells transfected with the PE-encoding plasmid is more pronounced than the decrease in cell number for the control group. For later experiments, we used subtoxic doses of cationic lipids to avoid the lipid toxicity as a side effect. Although counting total cells is a direct way of measuring PE gene activity, the cells are counted at 24 hours posttransfection; at that time, cells that have not been transfected can overgrow and mask the actual effect of the transfection. For these reasons, we do not consider this assay to be sensitive enough to estimate the transfection yield of our plasmid.
To examine the toxicity of the lipids versus the toxicity of the expressed PE, we performed a cytotoxicity assay. Figure 3 shows a cytotoxicity assay performed on A431 cells that were treated with increasing amounts of DNA (either pULI100 or pELI92) with a similar amount of DOSPER for every concentration (ratio of 1:4 DNA to DOSPER, respectively). The IC 50 for cells treated with PE-expressing plasmid was 65 g/mL, whereas the IC 50 for the control plasmid was 90 g/mL.
Another way to measure the efficiency of transfection with the PE gene is to cotransfect cells with the two plasmids; a PE-encoding plasmid (pULI100) and a ␤-gal-encoding plasmid (pELI92). Cells transfected with both plasmids undergo apoptosis, resulting in a decrease in ␤-gal expression. Figure 4 shows the results of cotransfection of two different cell lines, A431(epidermoid carcinoma) and MCF7 (breast carcinoma) with both the PE-encoding plasmid (pULI100) and the ␤-gal-encoding plasmid (pELI92). Transfection was done with both cationic lipid reagents. The amount of pELI92 was kept Cotransfection of both pULI100 and pELI92 plasmids was done in two different cell lines, A431 and MCF7, with both cationic lipid reagents. Cotransfection was done using a constant amount of pELI92 (1 g/well) and increasing amounts of pULI100. Each experiment was done in duplicate.
constant at 1 g/well, and it was cotransfected with increasing amounts of pULI100. As seen in Figure 4 , even with as little as 0.01 g of the PE-encoding plasmid (pULI100), we observe a dramatic reduction in the ␤-gal expression for both cell lines and with both cationic lipid reagents (a Ͼ50% reduction in ␤-gal expression in A431 cells transfected with DOSPER). Transfection with 0.1 g of the PE-encoding plasmid resulted in an almost complete eradication of ␤-gal expression in A431 cells with both transfection reagents. A similar pattern was observed in the MCF7 cell line. It is important to note that in all experimental wells, the lipid amount was subtoxic, and a protein assay showed a similar amount of protein in all wells, suggesting that the decrease in ␤-gal expression was due to expression of the toxin and was not a side effect of the toxicity. The need for as little as a 1:100 wt/wt ratio of pULI100 and pELI92 to cause cell death in Ͼ50% of ␤-gal-expressing cells could be due to the fact that cell death is induced with very low expression levels of PE; in contrast, higher expression is needed in the cell to produce a detectable amount of ␤-gal, and that can only result with transfection of multiple copies of the plasmid into each cell.
Antitumor effect
To determine whether we could use the lethal potential of the PE-encoding plasmid to kill tumor cells in vivo, complexes of DNA and DOSPER or DNA and DOGS were injected into tumors composed of A431 cells and MCF7ras cells growing in athymic nude mice. Complexes of DNA with DOGS showed a lower efficiency of transfection, as was expected from our in vitro studies (data not shown). Transfection was done by direct injections into the tumors, because most experiments with cationic liposome-DNA complexes that are administered intravenously have been found mainly to transfect cells in the lungs, and to a lesser extent in the spleen, heart, liver, kidneys, and other organs. 16, 19 Because the cationic lipids do not have any specificity for tumor cells, and because transfecting other organs with the PEencoding plasmid can result in extensive damage to those organs, the intratumoral route of administration was chosen. Figure 5 shows transfections that were done on A431 tumor-bearing mice. Intratumoral injections were done on days 4, 6, and 8. The figure shows a very slow pattern of growth for the tumors transfected with the PEencoding plasmid, whereas the control untreated tumors grew quite rapidly (P ϭ .005 for day 12). In another experiment, tumors treated in the same manner with a control nontoxin plasmid were found to behave the same as untreated tumors (P ϭ .75 for day 18). Because of the rather large SD, experiments were repeated four times to verify the overall result. All experiments had the same profile of attenuated growth in treated tumors compared with controls (P ϭ .003 for combined experiments on day 11). Figure 6 shows a similar experiment done with MCF7ras tumor-bearing mice. This cell line, although very easily transfected in vitro, grows slower as a xenograft in athymic nude mice. 20 For that reason, this cell line was transplanted in a suspension of ECM matrigel to enhance the xenograft take. 20 As seen in Figures 5  and 6 , MCF7ras tumors treated with the PE-encoding plasmid complexed to DOSPER showed not only a slower growth profile but also a decrease in initial tumor size when compared with A431 tumors. The control group in this experiment was treated with the ␤-galencoding plasmid complexed to DOSPER. Control tumors grew faster than those for the treatment group (P ϭ .0003 for day 32) although not as fast as A431 control tumors. This slower growth pattern is attributed to the nature of this tumor rather than a result of the transfection with DNA complexed to cationic lipids, as untreated MCF7ras tumors grow as slowly (P ϭ .38 on day 15). 
DISCUSSION
The toxic potency of PE was used to reduce the tumor size of tumor xenografts in athymic nude mice by transfecting the tumor cells in vivo via cationic liposomes.
We initially examined how different ratios between the plasmid DNA and the cationic lipid reagents affect the transfection yield in vitro. This was done to get an idea of the ratio range that should be used for the in vivo studies. The transfection level was measured by assay of ␤-gal expression. We found that the two cationic lipid reagents that were used in this study, DOGS and DOSPER, had different transfection profiles, resulting in a higher transfection yield for DOSPER in all of the cell lines examined. Although a ratio of 1:10 wt/wt DNA to lipid, respectively, was found to give the highest transfection results for both reagents, a ratio of 1:4 was comparable with the transfection yield of the ratio 1:10 in the case of DOSPER. A ratio of 1:4 DNA to lipid, respectively, was later used for our in vivo study because it was desired to keep the intratumoral injection volume low.
We then tried to detect cell death within a population of cells transfected with the PE-encoding plasmid (pULI100). We determined the expression of PE as well as the subsequent cell killing following its expression in several ways. The direct way was to measure cell number at 24 hours posttransfection. Although direct, this measurement is sometimes masked with the growth of nontransfected cells. We also compared the cytotoxicity of the PE plasmid complexed to the lipid reagent with the toxicity of a control plasmid complexed to the same lipid reagent to estimate the subtoxic level of the lipid itself; so that we could use subtoxic amounts of DNA to lipid complexes for later experiments. This cytotoxicity assay also showed the specific activity of the expressed PE compared with the toxicity of the lipid reagent itself.
Another way to determine the expression of PE was to detect the reduction of ␤-gal expression in cells that were cotransfected with both ␤-gal-encoding and PEencoding plasmids. Those results showed that transfection of small amounts of plasmid, not detectable with a reporter gene, is sufficient for the expression of enough PE molecules to cause cell death, and therefore a decrease in ␤-gal expression in cotransfected cells. Most reporter genes are detected with assays that are limited in their sensitivity; therefore, only transfection of multiple copies of plasmid can result in expression that is high enough for detection. Of course PE could also be expressed after multiple plasmid transfection, only to express enough PE to be lethal for the cell, and the plasmid copy number needed is probably much lower than that needed to express ␤-gal in a detectable amount. This indirect means of measuring in vitro the activity of the PE-encoding plasmid by cotransfecting it with another reporter gene is a useful way to estimate the transfection yields of different transfection reagents, because this method is very sensitive and is not limited to the sensitivity of the reporter gene expression assay.
Those results encouraged us to carry out in vivo studies even though it is known that transfection in vivo is not always a very efficient procedure. Although cationic liposomes do not yield very high transfection rates compared with viral vectors, they are becoming a transfection reagent of choice for many in vivo applications because of their low immunogenicity. In our in vivo studies, we showed that due to the high toxicity of PE, the comparatively low transfection yield of cationic lipid reagents was not an obstacle, and the transfection results clearly indicated a decrease in growth rate or a regression of tumor xenografts transfected with the PE-encoding plasmid. In the current studies, only three injections were administered every other day. Presumably, more frequent injections or an increase of the number of injections would have a more profound effect on attenuation of tumor growth.
We have shown that local delivery of a PE-encoding plasmid complexed with cationic liposomes is feasible and results in a significant delay in tumor growth in the nude mouse model. Because local treatment of many epithelioid carcinomas remains suboptimal despite the best conventional therapy, transfection with PE-encoding plasmids warrants further investigation as a treatment option either alone or in combination with other chemotherapy and radiotherapy.
